1. Home
  2. Directory
  3. Michigan
  4. Royal Oak
  5. Nurse Practitioner
  6. NPI Profile
  7. Prescriptions 1669967618

MS. ASHLEIGH TERRELL NP-C
Prescription History 1669967618
Nurse Practitioner in Royal Oak, MI


Quality Rating: 80.99 out of 100 score

NPI Status: Active since June 22, 2018

Contact Information

3555 W 13 MILE RD STE N120
ROYAL OAK, MI
ZIP 48073
Phone: (855) 863-8761
Fax: (248) 551-2301

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for MS. ASHLEIGH TERRELL NP-C, an active Nurse Practitioner specialist practicing in Royal Oak, MI. Our medical registry currently tracks 10 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 214 documented patient claims. Among these therapy options, the most frequently utilized medication is Lacosamide, which accounts for 35 claims alone.

Medication Index

Aptiom

Generic Formulation: Eslicarbazepine AcetateSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 14
30-Day Fills 18.0
Days Supply 540
MI State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills29.6
Peer Average Days Supply808
Conservative Utilization

This provider writes prescriptions for this formulation 46.2% less frequently than the standard regional baseline metric for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $29,776.84 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,126.92

State Avg Cost Per Claim

$1,584.56

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Eslicarbazepine is used alone or with other medications to treat a certain type of seizure disorder (focal seizures). It belongs to a class of drugs known as anticonvulsants. Eslicarbazepine may reduce the number of seizures you have.

Briviact

Generic Formulation: BrivaracetamSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 22
30-Day Fills 26.0
Days Supply 780
MI State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills38.6
Peer Average Days Supply1,077
Conservative Utilization

This provider writes prescriptions for this formulation 37.1% less frequently than the standard regional baseline metric for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $49,769.90 across this reporting matrix range.

Provider Avg Cost Per Claim

$2,262.27

State Avg Cost Per Claim

$1,589.10

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Brivaracetam is used to treat seizures (epilepsy).

Clobazam

Generic Formulation: ClobazamSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 31
30-Day Fills 35.0
Days Supply 994
MI State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills43.4
Peer Average Days Supply1,243
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,118.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$132.85

State Avg Cost Per Claim

$247.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.

Therapeutic Applications

This medication is used with other medications to help control seizures. It belongs to a class of medications called benzodiazepines, which act on the brain and nerves (central nervous system) to produce a calming effect. This drug works by enhancing the effects of a certain natural chemical in the body (GABA).

Divalproex Sodium

Generic Formulation: Divalproex SodiumSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 13
30-Day Fills 15.1
Days Supply 454
MI State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills52.2
Peer Average Days Supply1,448
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 70.5% less volume than the regional standard for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $670.75 across this reporting matrix range.

Provider Avg Cost Per Claim

$51.60

State Avg Cost Per Claim

$44.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.

Therapeutic Applications

This medication is used to treat seizure disorders, certain psychiatric conditions (manic phase of bipolar disorder), and to prevent migraine headaches. It works by restoring the balance of certain natural substances (neurotransmitters) in the brain.

Epidiolex

Generic Formulation: Cannabidiol (Cbd)Specialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 16
30-Day Fills 20.0
Days Supply 600
MI State Average Benchmarks
Peer Average Claims42.0
Peer Average 30-Day Fills45.2
Peer Average Days Supply1,330
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 61.9% less volume than the regional standard for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $152,412.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$9,525.80

State Avg Cost Per Claim

$4,653.65

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Compound isolated from Cannabis sativa extract.

Therapeutic Applications

This medication is used to treat seizures due to certain medical conditions (such as Lennox-Gastaut syndrome, Dravet syndrome, tuberous sclerosis complex - TSC). It is not known how this medication works for these seizures. Cannabidiol belongs to a class of drugs known as cannabinoids.

Lacosamide

Generic Formulation: LacosamideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 35
30-Day Fills 47.0
Days Supply 1,410
MI State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills44.8
Peer Average Days Supply1,195
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $7,358.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$210.23

State Avg Cost Per Claim

$267.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.

Therapeutic Applications

Lacosamide is used to prevent and control seizures. It is an anticonvulsant or antiepileptic drug. It works by reducing the spread of seizure activity in the brain.

Lamotrigine

Generic Formulation: LamotrigineSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 19
30-Day Fills 33.0
Days Supply 990
MI State Average Benchmarks
Peer Average Claims48.0
Peer Average 30-Day Fills72.7
Peer Average Days Supply2,129
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 60.4% less volume than the regional standard for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $439.10 across this reporting matrix range.

Provider Avg Cost Per Claim

$23.11

State Avg Cost Per Claim

$17.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenyltriazine compound, sodium and calcium channel blocker that is used for the treatment of SEIZURES and BIPOLAR DISORDER.

Therapeutic Applications

Lamotrigine is used alone or with other medications to prevent and control seizures. It may also be used to help prevent the extreme mood swings of bipolar disorder in adults. Lamotrigine is known as an anticonvulsant or antiepileptic drug. It is thought to work by restoring the balance of certain natural substances in the brain. This drug is not approved for use in children younger than 2 years due to an increased risk of side effects (such as infections).

Levetiracetam

Generic Formulation: LevetiracetamSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 31
30-Day Fills 49.1
Days Supply 1,474
MI State Average Benchmarks
Peer Average Claims46.0
Peer Average 30-Day Fills70.7
Peer Average Days Supply2,037
Conservative Utilization

This provider writes prescriptions for this formulation 32.6% less frequently than the standard regional baseline metric for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,506.11 across this reporting matrix range.

Provider Avg Cost Per Claim

$80.84

State Avg Cost Per Claim

$48.01

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.

Therapeutic Applications

Levetiracetam is used to treat seizures (epilepsy). It belongs to a class of drugs known as anticonvulsants. Levetiracetam may decrease the number of seizures you have.

Oxtellar Xr

Generic Formulation: OxcarbazepineSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 358
MI State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills22.8
Peer Average Days Supply634
Conservative Utilization

This provider writes prescriptions for this formulation 42.9% less frequently than the standard regional baseline metric for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $8,191.40 across this reporting matrix range.

Provider Avg Cost Per Claim

$682.62

State Avg Cost Per Claim

$1,146.05

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4.

Therapeutic Applications

Oxcarbazepine is used alone or with other medications to treat seizure disorders (epilepsy).

Zonisamide

Generic Formulation: ZonisamideSpecialty: Nurse Practitioner
Provider Metrics Summary
Total Claims 21
30-Day Fills 48.6
Days Supply 1,458
MI State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills50.6
Peer Average Days Supply1,486
Conservative Utilization

This provider writes prescriptions for this formulation 32.3% less frequently than the standard regional baseline metric for practitioners inside MI. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,752.14 across this reporting matrix range.

Provider Avg Cost Per Claim

$83.44

State Avg Cost Per Claim

$48.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.

Therapeutic Applications

Zonisamide is used with other medications to prevent and control seizures (epilepsy). Zonisamide is a sulfonamide anticonvulsant and a carbonic anhydrase inhibitor. It is unknown how zonisamide works to prevent seizures.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like MS. ASHLEIGH TERRELL NP-C provides transparency into local medical care patterns within Royal Oak, MI.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Nurse Practitioner** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.